Prostate Cancer Foundation Awards $6.1 Million to Record Number of Competitive Award Recipients
The 2006 PCF Competitive Award Program Presented a Record 63 Research Investigators with Grants to Aggressively Search for Better Treatments and a Cure for Prostate Cancer
March 2, 2007 -- The Prostate Cancer Foundation (PCF) announced today the recipients of the its 2006 Competitive Awards Program. The program granted a total of $6.1 million to 63 research investigators from four countries, of whom 30 were first-time awardees.
The Competitive Awards Program is an innovative venture-style research funding program that provides financial support to high-impact research projects with the greatest potential to improve survival and reduce side effects and death for men with advanced prostate cancer. The awards are granted to projects in a variety of areas including biomarkers, genetics and genomics, nutrition, cancer immunotherapy, new drug discovery and survivorship.
"The PCF Competitive Awards Program concentrates funds entrusted to us by our donors into the most strategic science," said Stuart Holden, MD, medical director of the PCF. "This year, we received more than 420 applications from 22 countries and were able to provide a record 63 projects a decisive boost in funding."
With its model of drawing new investigators around the globe to the field and enabling investigators to attract additional significant investment, the Competitive Awards Program has played a unique role in the area of prostate cancer research. To date, more than $81 million has been awarded through the Competitive Awards Program, allowing individual investigators to focus their efforts on discovering new ideas and new pathways for prostate cancer treatment strategies.
"We at the PCF are proud of our role in advancing scientific and medical understanding of this disease and identifying new approaches to defeating it," said Jonathan W. Simons, MD, chief executive officer and president of the PCF. "The PCF continues to leverage and invest every resource available to advance our mission to end death and suffering from prostate cancer."
Prostate cancer is the most common non-skin cancer in the United States, striking one in six men. In 2007 alone, more than 218,000 men will be diagnosed with prostate cancer and more than 27,000 men will die of the disease. Baby boomer men are turning 60, bringing increasing numbers of men into the highest-risk zone for the disease. As a result, the number of new cases over the next decade is expected to increase to more than 300,000 annually.
The Prostate Cancer Foundation 2006 Competitive Awards Program recipients are:
Baylor College of Medicine: Naijie Jing, PhD
BC Cancer Agency: Yuzhuo Wang, PhD
Beth Israel Deaconess Medical Center: Mark A. Exley, MSc, PhD; Xuesong Gu, PhD; Towia A. Libermann, PhD
Cleveland Clinic: Robert H. Silverman, PhD
Columbia University Medical Center: Edward P. Gelmann, MD
Dana-Farber Cancer Institute: Ronald A. DePinho, MD; Levi A. Garraway, MD, PhD; William C. Hahn, MD, PhD
Earle A. Chiles Research Institute: Bernard A. Fox, PhD
Hebrew University: Alexander Levitzki, PhD
Henry M. Jackson Foundation: Albert Dobi, PhD
Indiana University: Jian-Ting Zhang, PhD
Jewish General Hospital, a McGill University Teaching Hospital: Michael N. Pollak, MD
Johns Hopkins University: Michael A. Carducci, MD; Robert H. Getzenberg, PhD; John T. Isaacs, PhD; Jun O. Liu, PhD; Srinivasan Yegnasubramanian, MD, PhD
Massachusetts General Hospital: Matthew R. Smith, MD, PhD
Memorial Sloan-Kettering Cancer Center: James P. Allison, PhD; Neal Rosen, MD, PhD; Howard I. Scher, MD; Sven Wenske, MD
Mount Sinai School of Medicine: John A. Martignetti, MD, PhD
Ohio State University: Ching-Shih Chen, PhD
Sidney Kimmel Cancer Center: Michael McClelland, PhD
University of California, San Diego: Michael G. Rosenfeld, MD
University of California, Davis: Christopher P. Evans, MD
University of California, Los Angeles: David Heber, MD, PhD; Michael E. Jung, PhD; Owen N. Witte, MD; Lily Wu, MD, PhD
University of California, San Francisco: Robert H. Blelloch, MD, PhD; Heike E. Daldrup-Link, MD, PhD; Marc I. Diamond, MD; Timothy P. Quinn, MD; Eric J. Small, MD; Paul Webb, PhD
University of Connecticut Health Center: Linda H. Shapiro, PhD
University of Illinois: Jianjun Cheng, PhD
University of Louisville: La Creis R. Kidd, PhD, MPH
University of Michigan: Arul M. Chinnaiyan, MD, PhD; Robert D. Loberg, PhD; Russell S. Taichman, DMD, DMSc; Shaomeng Wang, PhD
University of Pittsburgh Cancer Institute: Denise S. O'Keefe, PhD
University of Regensburg: Christoph A. Klein, MD
University of Southern California: Christopher A. Haiman, ScD; Shi-Lung Lin, PhD; Mariana C. Stern, PhD
University of Texas M. D. Anderson Cancer Center: Sue-Hwa Lin, PhD; Renata Pasqualini, PhD; Padmanee Sharma, MD, PhD; Zhengxin Wang, PhD
University of Virginia: Michael J. Weber, PhD
University of Washington: Alvin Y. Liu, PhD
University of Wisconsin, Madison: Wade A. Bushman, MD, PhD
Vancouver General Hospital: Martin E. Gleave, MD
Vanderbilt University Medical Center: Robert J. Matusik, PhD
Weill Medical College of Cornell University: Ashutosh K. Tewari, MD, MCH
Yale University: Alan Garen, PhD
About the Prostate Cancer Foundation
The Prostate Cancer Foundation is the world’s largest philanthropic source of support for prostate cancer research focused on discovering better treatments and a cure for prostate cancer. Founded in 1993, the PCF has raised more than $370 million and provided funding to more than 1,500 research projects at nearly 200 institutions worldwide. The PCF also advocates for greater awareness of prostate cancer and more governmental research funds. PCF advocacy has helped produce a 20-fold increase in government funding for prostate cancer since 1994. More information about prostate cancer and the PCF can be found at www.pcf.org.